Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma
ConclusionsOur results indicate that the development of AEs to bevacizumab or bevacizumab-containing regimens is associated with unfavorable glioma-related survival outcomes in patients with rGB.
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
More News: Avastin | Brain | Brain Tumor | Databases & Libraries | Glioma | Neurology | Neuroscience | Statistics